Thermo Fisher Scientific (NYSE:TMO) Sets New 1-Year High – What’s Next?

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price hit a new 52-week high on Wednesday. The stock traded as high as $683.32 and last traded at $680.0990, with a volume of 711022 shares changing hands. The stock had previously closed at $679.61.

Analyst Ratings Changes

A number of analysts have recently issued reports on TMO shares. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and increased their price target for the stock from $540.00 to $730.00 in a research note on Tuesday, September 8th. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday. Finally, Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $628.78.

Thermo Fisher Scientific Stock Up 0.1%

The company has a market capitalization of $251.43 billion, a PE ratio of 36.57, a P/E/G ratio of 2.84 and a beta of 0.85. The business has a 50-day moving average of $612.25 and a 200 day moving average of $531.12. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. State Street Corp grew its holdings in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Capital World Investors raised its position in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares during the period. Franklin Resources Inc. boosted its position in shares of Thermo Fisher Scientific by 7.1% during the fourth quarter. Franklin Resources Inc. now owns 6,346,512 shares of the medical research company’s stock valued at $3,677,486,000 after buying an additional 420,841 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Thermo Fisher Scientific by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,724,476 shares of the medical research company’s stock valued at $2,158,148,000 after buying an additional 152,619 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.